Inventiva

Inventiva est une entreprise française biopharmaceutique dont le siège se situe à Daix. Elle développe deux candidats médicaments, lanifibranor et odiparcil, ainsi qu'un portefeuille de plusieurs programmes en stade préclinique.

Filings

100 filings

All Inside information100 Threshold crossing61 Earnings release13 Half-year financial report3 Universal registration document2 Quarterly financial information2

05/05/2025
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Inside informationFR
30/04/2025
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Inside information
30/04/2025
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires
Inside informationFrench
30/04/2025
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
Inside information
30/04/2025
Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025
Inside informationFrench
24/04/2025
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
Inside informationFR
15/04/2025
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inside informationFR
19/03/2025
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024
Inside informationFrench
26/02/2025
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Inside informationFR
20/02/2025
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inside informationFR
10/02/2025
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inside information
24/01/2025
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inside informationFR
22/01/2025
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Inside informationFR

About

ISIN: FR0013233012
Ticker: IVA
LEI: 969500I9Y690B3FZW590
Sector: Health care
Country of registration: FR
Last filing: 30/07/2026, 22:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive